Asbestos, chromosomal deletions, and tumor suppressor gene alterations in human malignant mesothelioma

Journal of Cellular Physiology

Volumn 180, Issue 2, 1999, Pages 150-157

  Murthy, Siva S ^a   Testa, Joseph R ^a  

^a FOX CHASE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASBESTOS; PROTEIN P53;

CANCER INHIBITION; CARCINOGENESIS; CHROMOSOME DELETION; CHROMOSOME MUTATION; CYTOGENETICS; GENE EXPRESSION; HUMAN; HUMAN CELL; MALIGNANT MESOTHELIOMA; MOLECULAR CLONING; MOLECULAR GENETICS; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; TUMOR SUPPRESSOR GENE;

ASBESTOS; CARCINOGENS; CHROMOSOME ABERRATIONS; CHROMOSOME DISORDERS; CYCLIN-DEPENDENT KINASE INHIBITOR P16; GENE DELETION; GENES, TUMOR SUPPRESSOR; HUMANS; MESOTHELIOMA; PLEURAL NEOPLASMS;

SIMIAE; SIMIAN VIRUS; SIMIAN VIRUS 40;

EID: 0033032327     PISSN: 00219541     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-4652(199908)180:2<150::AID-JCP2>3.0.CO;2-H     Document Type: Review

References (66)

1. Ault JG, Cole RW, Jensen CG, Jensen LC, Bachert LA, Rieder CL. 1995. Behavior of crocidolite asbestos during mitosis in living vertebrate lung epithelial cells. Cancer Res 55:792-798.
2. Balsara BR, Bell D, Sonoda G, De RienzoA, du Manoir S, Jhanwar S, Testa JR. 1998. Comparative genomic hybridization and loss of heterozygosity analyses identify 15q11.1-15 as a new region frequently deleted in malignant mesothelioma. Cancer Res (in press).
3. Baris YI, Saracci R, Simonato L, Skidmore JW, Artvinli M. 1981. Malignant mesothelioma and radiological chest abnormalities in two villages in Central Turkey. An epidemiological and environmental investigation. Lancet 1:984-987.
4. Barrett JC. 1994. Cellular and molecular mechanisms of asbestos carcinogenicity: implications for bio-persistence. Environ Health Perspect 102 (Suppl 5):19-23.
5. Bell DW, Jhanwar SC, Testa JR. 1997. Multiple regions of allelic loss from chromosome arm 6q in malignant mesothelioma. Cancer Res 57:4057-4062.
6. Bianchi AB, Mitsunaga SI, Cheng JQ, Klein WM, Jhanwar SC, Seizinger B, Kley N, Klein-Szanto AJP, Testa JR. 1995. High frequency of inactivating mutations in the neurofibromatosis type 2 gene (NF2) in primary malignant mesotheliomas. Proc Natl Acad Sci USA 92:10854-10858.
7. Bjorkqvist AM, Tammilehto L, Anttila S, Mattson K, Knuutila S. 1997. Recurrent DNA copy number changes in 1q, 4q, 6q, 9p, 13q, 14q, and 22q detected by comparative genomic hybridization in malignant mesothelioma. Br J Cancer 75:523-527.
8. Bjorkqvist AM, Tammilehto L, Nordling S, Nurminen M, Anttila S, Mattson K, Knuutila S. 1998. Comparison of DNA copy number changes in malignant mesothelioma, adenocarcinoma and large-cell anaplastic carcinoma of the lung. Br J Cancer 77:260-269.
9. Boutin C, Dumortier P, Rey F, Viallat JR, De Vuyst P. 1996. Black spots concentrate oncogenic asbestos fibers in the parietal pleura. Am J Respir Crit Care Med 153:444-449.
10. Carbone M, Rizzo P, Grimley PM, Procopio A, Mew DJ, Shridhar V, de Bartolomeis A, Esposito V, Giuliano MT, Steinberg SM, Levine AS, Giordano A, Pass HI. 1997a. Simian virus-40 large-T antigen binds p53 in human mesotheliomas. Nature Med 8:908-912.
11. Carbone M, Rizzo P, Pass HI. 1997b. Simian virus 40, poliovaccines and human tumors: a review of recent developments. Oncogene 15:1877-1888.
12. Cheng JQ, Jhanwar SC, Lu YY, Testa JR. 1993. Homozygous deletions within 9p21-p22 identify a small critical region of chromosomal loss in human malignant mesothelioma. Cancer Res 53: 4761-4763.
13. Cheng JQ, Jhanwar SC, Klein WM, Bell DW, Lee W-C, Altomare DA, Nobori T, Olopade OI, Buckler AJ, Testa JR. 1994. p16 alterations and deletion mapping of 9p21-p22 in malignant mesothelioma. Cancer Res 54:5547-5551.
14. Cheng JQ, Lee W-C, Klein MA, Cheng GZ, Jhanwar SC, Testa JR. 1997. Frequent alterations of NF2 and allelic loss from chromosome 22q12 in malignant mesothelioma: evidence for a two-hit mechanism of NF2 inactivation. Genes Chromosome Cancer (in press).
15. Cher ML, Bova GS, Moore DH, Small EJ, Carroll PR, Pin SS, Epstein JI, Isaacs WB, Jensen RH. 1996. Genetic alterations in untreated metastases and androgen-independent prostate cancer detected by comparative genomic hybridization and allelotyping. Cancer Res 56:3091-3102.
16. Churg A. 1988. Chrysotile, tremolite, and malignant mesothelioma in man. Chest 93:621-628.
17. Churg A. 1993. Asbestos lung burden and disease patterns in man. In: Gutherie G, Mossman BT, editors. Health effects of mineral dusts. Reviews in mineralology, vol. 28. Washington, DC, Mineralogical Society of America. p 410-426.
18. Churg A, Wright JL, Vedal S. 1993. Fiber burden and patterns of asbestos-related disease in chrysotile miners and millers. Am Rev Respir Dis 148:25-31.
19. Craighead JE, Mossman BT. 1982. The pathogenesis of asbestos-associated diseases. N Engl J Med 306:1446-1455.
20. De Luca A, Baldi A, Esposito V, Howard CM, Bagella L, Rizzo P, Caputi M, Pass HI, Giordano GG, Baldi F, Carbone M, Giordano A. 1997. The retinoblastoma gene family pRb/p105, p107, pRb2/p130 and simian virus-40 large T-antigen in human mesotheliomas. Nature Med 3:913-916.
21. Fearon ER, Vogelstein B. 1990. A genetic model for colorectal tumorigenesis. Cell 61:759-767.
22. Flejter WL, Li FP, Antman KH, Testa JR. 1989. Recurring loss involving chromosomes 1, 3, and 22 in malignant mesothelioma: possible sites of tumor suppressor genes. Genes Chromosome Cancer 1:148-154.
23. Frizelle SP, Grim J, Zhou J, Gupta P, Curiel DT, Geradts J, Kratzke RA. 1998. Re-expression of p16INK4a in mesothelioma cells results in cell cycle arrest, cell death, tumor suppression and tumor regression. Oncogene 16:3087-3095.
24. Fung H, Kow YW, Van Houten B, Taatjes DJ, Hatahet Z, Janssen YM, Vacek P, Faux SP, Mossman BT. 1998. Asbestos increases mammalian AP-endonuclease gene expression, protein levels, and enzyme activity in mesothelial cells. Cancer Res 58:189-194.
25. Gibas Z, Li FP, Antman KH, Bernai S, Stahel R, Sandberg AA 1986. Chromosome changes in malignant mesothelioma. Cancer Genet Cytogenet 20:191-201.
26. Hagemeijer A, Versnel MA, Van Drunen E, Moret M, Bouts MJ, van der Kwast TH, Hoogsteden HC. 1990. Cytogenetic analysis of malignant mesothelioma. Cancer Genet Cytogenet 47:1-28.
27. 2) from alveolar macrophages exposed to asbestiform and nonfibrous particles. Cancer Res 47:1681-1686.
28. Heintz NH, Janssen YM, Mossman BT. 1993. Persistent induction of c-fos and c-jun expression by asbestos. Proc Natl Acad Sci USA 90:3299-3303.
29. Hesterberg TW, Barrett JC. 1985. Induction by asbestos fibers of anaphase abnormalities: mechanism for aneuploidy induction and possibly carcinogenesis. Carcinogenesis 6:473-475.
30. Hesterberg TW, Chase G, Axten C, Miller WC, Musselman RP, Kamstrup O, Hadley J, Morscheidt C, Bernstein DM, Thevenaz P. 1998. Biopersistence of synthetic vitreous fibers and amosite asbestos in the rat lung following inhalation. Toxicol Appl Pharmacol 151:262-275.
31. Hussussian CJ, Struewing JP, Goldstein AM, Higgins PA, Ally DS, Sheahan MD, Clark WHJ, Tucker MA, Dracopoli NC. 1994. Germline p16 mutations in familial melanoma. Nature Genet 8:15-21.
32. Kamb A, Gruis NA, Weaver-Feldhaus J, Liu Q, Harshman K, Tavtigian SV, Stockert E, Day R, Johnson BE, Skolnick MH. 1994a. A cell cycle regulator potentially involved in the genesis of many tumor types. Science 264:436-440.
33. Kamb A, Shattuck-Eidens D, Eeles R, Liu Q, Gruis NA, Ding W, Hussey C, Tran T, Miki Y, Weaver-Feldhaus J, McClure M, Aitken JF, Anderson DE, Bergman W, Frants R, Goldgar DE, Green A, MacLennan R, Martin NG, Meyer LJ, Youl P, Zone JJ, Skolnick MH, Cannon-Albright LA. 1994b. Analysis of the p16 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus. Nature Genet 8:23-26.
34. Kivipenas P, Bjorkqvist AM, Karhu R, Pelin K, Linnainmaa K, Tammilehto L, Mattson K, Kallioniemi QP, Knuutila S. 1996. Gains and losses of DNA sequences in malignant mesothelioma by comparative genomic hybridization. Cancer Genet Cytogenet 89:7-13.
35. Knudson A. 1995. Asbestos and mesothelioma: genetic lessons from a tragedy. Proc Natl Acad Sci USA 92:10819-10820.
36. Kratzke RA, Otterson GA, Lincoln CE, Ewing S, Oie H, Geradts J, Kaye FJ. 1995. Immunohistochemical analysis of the p16INK4 cyclin-dependent kinase inhibitor in malignant mesothelioma. J Natl Cancer Inst 87:1870-1875.
37. Lee W-C, Balsara B, Liu Z, Jhanwar SC, Testa JR. 1996. Loss of heterozygosity analysis defines a critical region in chromosome 1p22 commonly deleted in human malignant mesothelioma. Cancer Res 56:4297-4301.
38. Linnainmaa K, Hirvonen A. 1997. SV40 virus DNA sequences are not present in the tumor tissue of Finnish mesothelioma patients. In: Proceedings of the Fourth International Mesothelioma Conference at the University of Pennsylvania, Philadelphia, Pennsylvania, May 13-15, 1997, p 30.
39. Lu YY, Jhanwar SC, Cheng JQ, Testa JR. 1994. Deletion mapping of the short arm of chromosome 3 in human malignant mesothelioma. Genes Chromosome Cancer 9:76-80.
40. Merlo A, Herman JG, Mao L, Lee DJ, Gabrielson E, Burger PC, Baylin SB, Sidransky D. 1995. 5' CpG island methylation is associated with transcriptional silencing of the tumor suppressor p16/ CDKN2/MTS1 in human cancers. Nature Med 1:686-692.
41. Mossman BT, Bignon J, Corn M, Seaton A, Gee JBL. 1990. Asbestos: scientific developments and implications for public policy. Science 247:294-300.
42. Mossman BT, Kamp DW, Weitzman SA. 1996. Mechanisms of carcinogenesis and clinical features of asbestos-associated cancers. Cancer Invest 14:466-480.
43. Nobori T, Miura K, Wu DJ, Lois A, Takabayashi K, Carson DA. 1994. Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature 368:753-756.
44. Offit K, Parsa NZ, Gaidano G, Filippa DA, Louie D, Pan D, Jhanwar SC, Dalla-Favera R, Chaganti RS. 1993. 6q deletions define distinct clinico-pathologic subsets of non-Hodgkin's lymphoma. Blood 82: 2157-2162.
45. Olofsson K, Mark J. 1989. Specificity of asbestos-induces chromosomal aberrations in short-term cultured human mesothelial cells. Cancer Genet Cytogenet 41:33-39.
46. Orphanos V, McGown G, Hey Y, Thorncroft M, Santibanez-Koref M, Russell SEH, Hickeym I, Atkinsonm RJ, Boyle JM. 1995. Allelic imbalance of chromosome 6q in ovarian tumors. Br J Cancer 71: 666-669.
47. Osborne RJ, Leech V. 1994. Polymerase chain reaction allelotyping of human ovarian cancer. Br J Cancer 69:429-438.
48. Pache JC, Janssen YM, Walsh ES, Quinlan TR, Zanella CL, Low RB, Taatjes DJ, Mossman BT. 1998. Increased epidermal growth factor-receptor protein in a human mesothelial cell line in response to long asbestos fibers. Am J Pathol 152:333-340.
49. Palmero I, Pantoja C, Serrano M. 1998. p19ARF links the tumour suppressor p53 to Ras. Nature 395:125-126.
50. Popescu NC, Chahinian AP, DiPaolo JA. 1988. Nonrandom chromosome alterations in human malignant mesothelioma. Cancer Res 48:142-147.
51. Seizinger BR, Klinger HP, Junien C, Nakamura Y, Le Beau M, Cavenee W, Emanuel B, Ponder B, Naylor S, Mitelman F, Louis D, Menon A, Newsham I, Decker J, Kaelbling M, Henry I, van Deimling A. 1991. Report of the committee on chromosome and gene loss in human neoplasia. Cytogenet Cell Genet 58:1080-1096.
52. Sekido Y, Pass HI, Bader S, Mew DJ, Christman MF, Gazdar AF, Minna JD. 1995. Neurofibromatosis type 2 (NF2) gene is somatically mutated in mesothelioma but not in lung cancer. Cancer Res 55:1227-1231.
53. Selikoff IJ. 1965. The occurrence of pleural calcification among asbestos insulation workers. Ann N Y Acad Sci 132:351-367.
54. Selikoff J, Hammond EC, Seidman H. 1979. Mortality experience of insulation workers in the United States and Canada 1943-1976. Ann N Y Acad Sci 330:91-116.
55. Selikoff IJ, Hammond EC, Seidman H. 1980. Latency of asbestos disease among insulation workers in the United States and Canada. Cancer 46:2736-2740.
56. Serrano M, Hannon GJ, Beach DA. 1993. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 366:704-707.
57. Sheng ZM, Marchetti A, Buttitta F, Champeme M-H, Campani D, Bistocchi M, Lidereau R, Callahan R. 1996. Multiple regions of chromosome 6q affected by loss of heterozygosity in primary human breast carcinomas. Br J Cancer 73:144-147.
58. Stott FJ, Bates S, James MC, McConnell BB, Starborg M, Brookes S, Palmero I, Ryan K, Hara E, Vousden KH, Peters G. 1998. The alternative product from the human CDKN2A locus, p14(ARF), participates in a regulatory feedback loop with p53 and MDM2. EMBO J 17: 001-5014.
59. Strickler HD, Goedert JJ, Fleming M, Travis WD, Williams AE, Rabkin CS, Daniel RW, Shah KV. 1996. Simian virus 40 and pleural mesothelioma in humans. Cancer Epidemiol Biomarkers Prev 5:473-475.
60. Taguchi T, Jhanwar SC, Siegfried JM, Keller SM, Testa JR. 1993. Recurrent deletions of specific chromosomal sites in 1p, 3p, 6q, and 9p in human malignant mesothelioma. Cancer Res 53:4349-4355.
61. Tahara H, Smith AP, Gas RD, Cryns VL, Arnold A. 1996. Genomic localization of novel candidate tumor suppressor gene loci in human parathyroid adenomas. Cancer Res 56:599-605.
62. Testa JR, Carbone M, Hirvonen A, Khalili K, Krynska B, Linnainmaa K, Pooley FD, Rizzo P, Rusch V, Xiao G-H. 1998. A multi-institutional study confirms the presence and expression of simian virus 40 in human malignant mesotheliomas. Cancer Res 58:4505-4509.
63. Tiainen M, Tammilehto L, Mattson K, Knuutila S. 1988. Non-random chromosomal abnormalities in malignant pleural mesothelioma. Cancer Genet Cytogenet 33:251-274.
64. Topping DC, Nettesheim P. 1980. Two-stage carcinogenesis studies with asbestos in Fischer 344 rats. J Natl Cancer Inst 65:627-630.
65. Wagner JC, Sleggs CA, Marchand P. 1960. Diffuse pleural mesotheliomas and asbestos exposure in the northwestern cape province. Br J Ind Med 12:260-271.
66. Wick W, Petersen I, Schmutzler RK, Wolfarth B, Lenartz D, Bierhoff E, Hummerich J, Muller DJ, Stangl AP, Schramm J, Wiestler OD, von Deimling A. 1996. Evidence for a novel tumor suppressor gene on chromosome 15 associated with progression to a metastatic stage in breast cancer. Oncogene 12:973-978.